ASH 2020

Annual Meeting & Exposition

American Society of Hematology

December 5-8, 2020
All-Virtual Meeting

Follow Fred Hutch at ASH: #ASH20 |  Facebook  |  Twitter

Fred Hutchinson Cancer Research Center’s latest findings on transplantation, cell therapies, precision medicine and more will be featured at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH).

This year's annual meeting will be held as a virtual event — featuring thousands of scientific abstracts highlighting updates on the most critical topics in hematology.

The ASH meeting provides an invaluable educational experience and the latest on the hottest topics in hematology. Attendess include top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.

 

Date:
Saturday-Tuesday, December 05-08, 2020
Location:
Virtual
Contact Information:

Read Our Media Tip Sheet Highlighting Research at ASH

ASH President Events

Dr. Stephanie Lee
Dr. Stephanie Lee is the current President of American Society of Hematology Photo by Robert Hood /Fred Hutch

Dr. Stephanie Lee

Professor and Associate Director, Clinical Research Division, Fred Hutch
Holder of the Giuliani/Oliver Press Endowed Chair in Cancer Research, Fred Hutch
President of American Society of Hematology

Fireside Chat
To kick off the ASH meeting, Dr. Lee will talk with Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, from 7a.m.-7:30 a.m. on Saturday, Dec. 5.

E. Donnall Thomas Lecture
Dr. Lee will chair the annual E. Donnall Thomas Lecture, named for the Hutch’s Nobel laureate Dr. Thomas, who would have turned 100 this year. This lectureship recognizes pioneering research achievements and is on Monday, Dec. 7, 1:30 p.m.-2:30 p.m.

Presidential Symposium
Dr. Lee will chair the discussion "Universal Donor Solutions in Hematology" on Tuesday, Dec. 8, 9:30 a.m. -11 a.m.

Follow Dr. Lee

Featured Events

Dr. Sinéad Kinsella

Dr. Sinéad Kinsella

Damage-Induced Pyroptotic Cell Death Facilitates Regeneration of the Thymus

Dr. Kinsella, a researcher in the lab of Dr. Jarrod Dudakov, will present findings on a new way of thymus regeneration in which a cell death process called pyroptosis is critical in releasing large numbers of signaling molecules that can trigger the thymus to repair itself.

Abstract No. 735

Monday, Dec. 7, 2:45 p.m.

Dr. Mayzar Shadman

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Dr. Shadman will share early results from the ongoing trial taking place at the Seattle Cancer Care Alliance, the Hutch’s clinical-care partner. 

Abstract No. 1443

Saturday, Dec. 5, 7 a.m.-3:30 p.m.

Dr. Elizabeth Krakow

Dr. Elizabeth Krakow

Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress

Dr. Krakow will present a phase I trial in progress. It uses a T-cell receptor therapy developed by Dr. Marie Bleakley  to treat adult and pediatric patients who have relapsed after receiving a stem cell (blood and marrow) transplant for leukemia or other related conditions.

Abstract No. 492

Sunday, Dec. 6, 2:15 p.m.

Highlights of Fred Hutch Presentations at ASH

Cellular Therapies  |  Transplantation and Other Clinical Studies  |  Precision Medicine and AML  |  Health Economics   |  Gene Editing  |  Cell Biology

 

Cellular Therapies

Scientific Workshop: Age, performance status, and comorbidities in relation to IEC-associated toxicities (including ICANS) followed by live Q&A panel discussion
Presenter: Jordan Gauthier, M.D.
Thursday, Dec. 3, 2:45 p.m.-3:17 p.m.

Poster Presentation: High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics
Presenter: Jordan Gauthier, M.D., M.SC.
Abstract No. 1442
Saturday, Dec. 5, 7 a.m.-3:30 p.m.
ASH Virtual Poster Walk:  Thursday, Dec. 10, 7 a.m.

Follow Dr. Gauthier


Poster Presentation:
Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Abstract No. 1443
Presenter: Mazyar Shadman, M.D.
Saturday, Dec. 5, 7 a.m. to 3:30 p.m.

Follow Dr. Shadman


Scientific Program, Live Q&A:
 Challenges in Cell Therapy: Relapse and Toxicities
Presenter: Aude Chapuis, M.D.
Saturday, Dec. 5, 9:30 a.m.-10:15 a.m.

Poster Presentation: Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy
Abstract No. 1959
Presenter: Quy Le, Ph.D.
Sunday, Dec. 6, 7 a.m.-3:30 p.m.

Poster Presentation: A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines
Abstract No. 3265
Presenter: Melinda ann Biernacki, M.D.
Monday, Dec. 7, 7 a.m. - 3:30 p.m.

Poster Presentation: CD19 CAR T-cell
Abstract No. 3485
Presenter: Erin Mullane, D.N.P.
Monday, Dec. 7, 7 a.m.-3:30 p.m.

Poster Presentation: Novel CAR T Modules (Tmod) to Target HLA-Class I Loss in Lymphoma
Abstract No. 3370
Presenter: David Maloney, M.D., Ph.D.
Monday, Dec. 7, 7a.m.-3:30p.m.
 

Transplantation and Other Clinical Studies

Oral Presentation: Cytomegalovirus Promotes Aberrant Memory CD4 T Cell Differentiation and Immune Function after Allogeneic Stem Cell Transplantation
Abstract No. 423
Presenter: Albert Yeh, M.D.
Sunday, Dec. 6, 1:15 p.m.

Poster Presentation: Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression
Abstract No. 2111
Presenter: Stephen D. Smith, M.D.
Sunday, Dec. 6, 7a.m.-3:30p.m.

Poster Presentation: Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib
Abstract No. 2947
Presenter: Mayzar Shadman, M.D., M.P.H.
Monday, Dec. 7, 7a.m.-3:30p.m.

Poster Presentation: Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Abstract No. 2935
Presenter: Ryan C. Lynch, M.D.
Monday, Dec. 7, 7a.m.-3:30p.m.

Precision Medicine and AML

Oral Presentation: Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts
Abstract No. 274
Presenter Rhonda E. Ries, M.A.
Saturday, Dec. 5, 2:30

Poster Presentation: Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia
Abstract No. 1993
Presenter: Katherine Tarlock, M.D.
Sunday, Dec. 6, 7 a.m.-3:30 p.m.

Poster Presentation: Target-Informed Repurposing of Immunotherapies in AML — a Transcriptome Based Approach for Identifying Immediately Available Therapeutics
Abstract No. 2003
Presenter: Amanda R. Leonti, M.S.
Sunday, Dec. 6, 7 a.m.-3:30 p.m.
 

Health Economics

Poster Presentation: Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada
Abstract No. 2516
Presenter: Andrew J. Cowan, M.D. (co-author Veena Shankaran, M.D.)
Sunday, Dec. 6, 7 a.m.-3 p.m.

Follow Dr. Cowan

Follow Dr. Shankaran


 

Gene Editing

Cell Biology

Oral Presentation: Damage-Induced Pyroptotic Cell Death Facilitates Regeneration of the Thymus
Abstract No. 735
Presenters: Sinéad Kinsella, M.Sc., Ph.D and Jarrod A. Dudakov, Ph.D.
Monday, Dec. 7, 2:45 p.m.

Follow Dr. Kinsella

Follow Dr. Dudakov

Contact Our Media Relations Team

For more information or to arrange an interview, please email or call our media relations team.

Last Modified, November 19, 2020